MYCOPHENOLATE MOFETIL, Rilvegostomig, RAMUCIRUMAB, INFLIXIMAB clinical trials

A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

This study is looking at new combinations of medicines for advanced non-small cell lung cancer. Researchers want to see if these combinations are safe, how they work in the body, and if they can shrink tumours. It's a key step in finding better treatments for this type of cancer.